肿瘤相关高血压整合管理中国专家共识(2024年版)  

Chinese expert consensus on integrated management of cancer-related hypertension(2024 version)

作　　者：中国抗癌协会整合肿瘤心脏病学分会 《肿瘤相关高血压整合管理中国专家共识》专家组 李悦 张志仁 卜军[3] 陈佳艺[4] 马飞[5] 夏云龙 谢晓冬 张梅[8] Society of Integrative Cardio-Oncology,China Anti-Cancer Association;Expert Panel on Chinese Expert Consensus on Integrated Management of Cancer-Related Hypertension;Yue Li;Zhiren Zhang

机构地区：[1]不详 [2]哈尔滨医科大学附属第一医院 [3]上海交通大学医学院附属仁济医院 [4]上海交通大学医学院附属瑞金医院 [5]中国医学科学院肿瘤医院 [6]大连医科大学附属第一医院 [7]中国人民解放军北部战区总医院 [8]山东大学齐鲁医院

出　　处：《中国肿瘤临床》2024年第19期993-1002,共10页Chinese Journal of Clinical Oncology

摘　　要：肿瘤相关高血压(cancer-related hypertension,CR-HTN)是恶性肿瘤患者常见且重要的临床问题,导致患者预后不良,尚缺乏统一认识和规范化管理。中国抗癌协会整合肿瘤心脏病学分会结合临床研究证据和实践经验制订本共识,详细介绍CR-HTN的流行病学、发病机制、诊断与鉴别诊断、治疗、预后和随访等内容,提出主动血压监测策略以早期发现CR-HTN,采用降压与抗肿瘤治疗的整合管理模式规范管理CR-HTN,提升我国CR-HTN诊治水平。Cancer-related hypertension(CR-HTN)is a common and significant clinical issue in cancer patients,leading to poor prognosis.However,there is still a lack of unified understanding and standardized management for this condition.The Society of Integrative Cardio-Oncology,China Anti-Cancer Association,has developed this consensus based on clinical research evidence and practical experience.It provides a detailed overview of the epidemiology,pathogenesis,diagnosis and differential diagnosis,treatment,prognosis,and follow-up of CR-HTN.The consensus advocates for a proactive blood pressure monitoring strategy to detect CR-HTN early and recommends an integrated approach combining anti-hypertensive and anti-cancer therapies to standardize the management of CR-HTN,thereby improving the diagnosis and treatment levels of CR-HTN in China.

关 键 词：高血压 恶性肿瘤 肿瘤心脏病 

分 类 号：R544.1[医药卫生—心血管疾病] R730.6[医药卫生—内科学]